Antisense Therap Ltd (ATHJF) 0.0400 $ATHJF
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 24.26 (+0.04), ALKS: 48.03 (+1.36), ARGS: 4.54 (-0.17), ABBV: 67.39 (+0.20), ATHX: 2.02 (+0.07), ARNA: 1.71 (+0.04), ARRY: 3.65 (+0.12)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 14.81 (+0.63), ADRO: 16.10 (+0.41), AMBX: (), ARQL: 1.50 (+0.01), ADMP: 2.65 (unch), AMGN: 174.58 (+1.56), APTO: 2.20 (-0.02), ATNM: 1.72 (+0.03), AVXL: 3.54 (-0.16), ABBV: 67.39 (+0.20)
Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 9.69 (+0.38), ADMP: 2.65 (unch), AMGN: 174.58 (+1.56), ACOR: 24.26 (+0.04), CLBS: 6.01 (-0.14), AZN: 33.44 (-0.10), ARRY: 3.65 (+0.12)
Acromegaly - Pipeline Review 2015
M2 - Fri Jan 29, 10:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcvj9g/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acromegaly Overview - Therapeutics Development - Pipeline Products for Acromegaly - Overview - Pipeline Products for Acromegaly - Comparative Analysis - Acromegaly - Therapeutics under Development by Companies - Acromegaly - Therapeutics under Investigation by Universities/Institutes - Acromegaly - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acromegaly - Products under Development by Companies - Acromegaly - Products under Investigation by Universities/Institutes - Acromegaly - Companies Involved in Therapeutics Development Companies Mentioned: - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Peptron, Inc. - Sompharmaceuticals S.A. - Strongbridge Biopharma plc For more information visit http://www.researchandmarkets.com/research/tcvj9g/acromegaly
ISIS: 57.56 (-0.28), SBBP: 4.34 (+0.04), CHMA: 2.94 (+0.03), NVS: 82.34 (+0.26)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 15.37 (-0.32), GSK: 44.40 (+0.23), SYN: 1.72 (unch), OPXA: 4.18 (-0.01), FWP: 22.90 (+1.65), TEVA: 54.54 (+0.68), ABBV: 67.39 (+0.20), NVS: 82.34 (+0.26)
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 35.11 (+0.13), GSK: 44.40 (+0.23), CNCE: 11.27 (+0.28), AZN: 33.44 (-0.10), SHPG: 198.89 (-0.04), CCXI: 4.37 (+0.05), ABBV: 67.39 (+0.20), TBRA: 5.07 (+0.46), XOMA: 0.61 (unch)
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.55 (+0.01), LPTN: 1.82 (-0.05)
PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis
M2 - Fri Sep 25, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nl5w7p/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report to their offering. "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, we provide an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics. Key Questions Answered - What are the drivers of the RNAi therapy field? - Who are the leading companies involved in the development of RNAi therapies? - What are the major trends in RNAi clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the antisense/RNAi therapy field? Scope - This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments - Investment examined from both industry and financial communities - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activities - Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Report Scope 2.2 Companies Mentioned 2.3 Related Reports 3 Antisense RNAi Therapy Overview 3.1 What is Antisense Therapy? 3.2 The Second Era of RNAi 4 Clinical Trials 4.1 Overview 4.2 Company 4.3 Phase of Development 4.4 Therapy Area 4.5 Indication 4.6 Investigators 5 Company Analysis 5.1 Overview 5.2 Pipeline Profiles 6 Deals Landscape 6.1 Overview 6.2 Deal Type 7 Strategic Outlook 8 Appendix Companies Featured: - Alnylam Pharmaceuticals - Antisense Therapeutics - Arrowhead Research Corporation - AuraSense Therapeutics - BioMarin Pharmaceuticals - Dicerna Pharmaceuticals - Gene Signal International SA - Idera Pharmaceuticals - InDex Pharmaceuticals AB - Isarna Therapeutics GmbH - Isis Pharmaceuticals - Miragen Therapeutics - Mirna Therapeutics - Moderna Therapeutics - Mologen AG - Oncogenex Pharmaceuticals - Quark Pharmaceuticals - Regulus Therapeutics - RXi Pharmaceuticals - Sarepta Therapeutics - Silence Therapeutics Plc - Sirnaomics - Sterna Biologicals GmbH - Sylentis SA - Tekmira (Arbutus) Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/nl...armasphere
ISIS: 57.56 (-0.28), IDRA: 2.00 (+0.01), DRNA: 3.71 (+0.26), ARWR: 6.12 (+0.16), SRPT: 25.98 (+0.72), RGLS: 3.64 (+0.09), MIRN: 4.02 (-0.18)
Diabetic Retinopathy Therapeutics Pipeline Review, H1 2015 - 34 Companies & 50 Drug Profiles
M2 - Tue Jul 21, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fgxcs/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Aprogen, Inc. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - MacuCLEAR, Inc. - MingSight Pharmaceuticals - Molecular Design International, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - PanOptica, Inc. - Promedior, Inc. - R-Tech Ueno, Ltd. - Resolvyx Pharmaceuticals, Inc - RestorGenex Corporation - Sirnaomics, Inc. - Stelic Institute & Co. - Stemedica Cell Technologies, Inc. - Targazyme, Inc. - ThromboGenics NV - TWi Pharmaceuticals, Inc. Drug Profiles - 49-B - A-6 - A-717 - AC-301 - AKB-9778 - ALG-1001 - AP-202 - ATL-1103 - BDM-E - Beta-LGND2 - CLT-01001 - CLT-01007 - CLT-01012 - cyclosporine - Cyndacel-M - DG-3173 - DMX-200 - Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - DT-23552 - E-1086 - EG-Mirotin - emixustat hydrochloride - FP-008 - IB-09A0133 - IMD-0354 - JP-153 - L-779976 - LCB-030110 For more information visit http://www.researchandmarkets.com/research/7fgxcs/diabetic
GTXI: 0.55 (+0.01), OHRP: 2.62 (+0.10)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 15.37 (-0.32), GSK: 44.40 (+0.23), XNPT: 7.07 (+0.05), SYN: 1.72 (unch), OPXA: 4.18 (-0.01), FWP: 22.90 (+1.65), TEVA: 54.54 (+0.68), ABBV: 67.39 (+0.20), NVS: 82.34 (+0.26)
Acromegaly Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtgwjc/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - GP Pharm, S.A. - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Paladin Labs Inc. - Peptron, Inc. - Sompharmaceuticals S.A. Drug Profiles - ATL-1103 - BIM-23A758 - DG-3173 - FP-002 - G-02113 - ISIS-GHRLRx - ITF-2984 - L-779976 - octreotide - octreotide acetate - octreotide acetate LAR - octreotide acetate long acting - octreotide acetate SR - octreotide SR - pasireotide LAR - pegvisomant - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Somadex - SXN-101742 - SXN-101959 For more information visit http://www.researchandmarkets.com/research/mtgwjc/acromegaly
ISIS: 57.56 (-0.28), CHMA: 2.94 (+0.03), NVS: 82.34 (+0.26)
Antisense Therapeutics Limited - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:26AM CDT
Product Pipeline Review - 2014
Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h4bvf/proliferative) has announced the addition of the "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Proliferative Diabetic Retinopathy (PDR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Diabetic Retinopathy (PDR) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Antisense Therapeutics Limited - Icon Bioscience, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - Sirnaomics, Inc. - ThromboGenics NV Drug Profiles - ATL-1103 - BI-30089 - Lycium Anti-Angiogenic Proteoglycan - OC-10X - ocriplasmin (recombinant) - squalamine lactate - STP-601 For more information visit http://www.researchandmarkets.com/research/2h...liferative
OHRP: 2.62 (+0.10)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.91 (-0.02), LLY: 80.26 (+0.04), GSK: 44.40 (+0.23), BMY: 60.03 (-0.60), CTIC: 0.35 (unch), CNCE: 11.27 (+0.28), JNJ: 122.31 (-0.91), GILD: 79.65 (-0.01), AZN: 33.44 (-0.10), CCXI: 4.37 (+0.05), ICPT: 165.05 (+2.06), ABBV: 67.39 (+0.20)
Cortendo and Antisense Therapeutics signs exclusive licensing agreement for ATL1103 for acromegaly
M2 - Fri May 15, 5:56AM CDT
Cortendo AB (NOTC-A:CORT) (OTC:CRTOF), a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited (ASX:ANP), an Australian biopharmaceutical drug discovery and development company, announced on Thursday the entering into an exclusive license agreement that provides Cortendo with development and commercialisation rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
CORT: 5.81 (+0.04)
Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
BusinessWire - Fri May 15, 1:41AM CDT
--Cortendo Expands Investor Base Through New Private Placement
Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
BusinessWire - Thu May 14, 6:53PM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 44.40 (+0.23), XNPT: 7.07 (+0.05), OPXA: 4.18 (-0.01), SYN: 1.72 (unch), ABBV: 67.39 (+0.20), TEVA: 54.54 (+0.68), NVS: 82.34 (+0.26)
Acromegaly - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqcstv/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acromegaly - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ipsen S.A. - Novartis AG - Antisense Therapeutics Limited - Paladin Labs Inc. - Camurus AB - GP Pharm, S.A. - Aegis Therapeutics, LLC - Peptron, Inc. - Q Chip Ltd. - Crinetics Pharmaceuticals, Inc. - Chiasma, Inc. - Foresee Pharmaceuticals, LLC - DexTech Medical AB For more information visit http://www.researchandmarkets.com/research/fqcstv/acromegaly
NVS: 82.34 (+0.26)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: 6.94 (+0.05), REGN: 422.87 (+1.33)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 24.26 (+0.04), ALKS: 48.03 (+1.36), ARGS: 4.54 (-0.17), ABBV: 67.39 (+0.20), ATHX: 2.02 (+0.07), ARNA: 1.71 (+0.04), ARRY: 3.65 (+0.12)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 14.81 (+0.63), ADRO: 16.10 (+0.41), AMBX: (), ARQL: 1.50 (+0.01), ADMP: 2.65 (unch), AMGN: 174.58 (+1.56), APTO: 2.20 (-0.02), ATNM: 1.72 (+0.03), AVXL: 3.54 (-0.16), ABBV: 67.39 (+0.20)
Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 9.69 (+0.38), ADMP: 2.65 (unch), AMGN: 174.58 (+1.56), ACOR: 24.26 (+0.04), CLBS: 6.01 (-0.14), AZN: 33.44 (-0.10), ARRY: 3.65 (+0.12)
Acromegaly - Pipeline Review 2015
M2 - Fri Jan 29, 10:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcvj9g/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acromegaly Overview - Therapeutics Development - Pipeline Products for Acromegaly - Overview - Pipeline Products for Acromegaly - Comparative Analysis - Acromegaly - Therapeutics under Development by Companies - Acromegaly - Therapeutics under Investigation by Universities/Institutes - Acromegaly - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acromegaly - Products under Development by Companies - Acromegaly - Products under Investigation by Universities/Institutes - Acromegaly - Companies Involved in Therapeutics Development Companies Mentioned: - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Peptron, Inc. - Sompharmaceuticals S.A. - Strongbridge Biopharma plc For more information visit http://www.researchandmarkets.com/research/tcvj9g/acromegaly
ISIS: 57.56 (-0.28), SBBP: 4.34 (+0.04), CHMA: 2.94 (+0.03), NVS: 82.34 (+0.26)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 15.37 (-0.32), GSK: 44.40 (+0.23), SYN: 1.72 (unch), OPXA: 4.18 (-0.01), FWP: 22.90 (+1.65), TEVA: 54.54 (+0.68), ABBV: 67.39 (+0.20), NVS: 82.34 (+0.26)
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 35.11 (+0.13), GSK: 44.40 (+0.23), CNCE: 11.27 (+0.28), AZN: 33.44 (-0.10), SHPG: 198.89 (-0.04), CCXI: 4.37 (+0.05), ABBV: 67.39 (+0.20), TBRA: 5.07 (+0.46), XOMA: 0.61 (unch)
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.55 (+0.01), LPTN: 1.82 (-0.05)
PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis
M2 - Fri Sep 25, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nl5w7p/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report to their offering. "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, we provide an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics. Key Questions Answered - What are the drivers of the RNAi therapy field? - Who are the leading companies involved in the development of RNAi therapies? - What are the major trends in RNAi clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the antisense/RNAi therapy field? Scope - This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments - Investment examined from both industry and financial communities - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activities - Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Report Scope 2.2 Companies Mentioned 2.3 Related Reports 3 Antisense RNAi Therapy Overview 3.1 What is Antisense Therapy? 3.2 The Second Era of RNAi 4 Clinical Trials 4.1 Overview 4.2 Company 4.3 Phase of Development 4.4 Therapy Area 4.5 Indication 4.6 Investigators 5 Company Analysis 5.1 Overview 5.2 Pipeline Profiles 6 Deals Landscape 6.1 Overview 6.2 Deal Type 7 Strategic Outlook 8 Appendix Companies Featured: - Alnylam Pharmaceuticals - Antisense Therapeutics - Arrowhead Research Corporation - AuraSense Therapeutics - BioMarin Pharmaceuticals - Dicerna Pharmaceuticals - Gene Signal International SA - Idera Pharmaceuticals - InDex Pharmaceuticals AB - Isarna Therapeutics GmbH - Isis Pharmaceuticals - Miragen Therapeutics - Mirna Therapeutics - Moderna Therapeutics - Mologen AG - Oncogenex Pharmaceuticals - Quark Pharmaceuticals - Regulus Therapeutics - RXi Pharmaceuticals - Sarepta Therapeutics - Silence Therapeutics Plc - Sirnaomics - Sterna Biologicals GmbH - Sylentis SA - Tekmira (Arbutus) Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/nl...armasphere
ISIS: 57.56 (-0.28), IDRA: 2.00 (+0.01), DRNA: 3.71 (+0.26), ARWR: 6.12 (+0.16), SRPT: 25.98 (+0.72), RGLS: 3.64 (+0.09), MIRN: 4.02 (-0.18)
Diabetic Retinopathy Therapeutics Pipeline Review, H1 2015 - 34 Companies & 50 Drug Profiles
M2 - Tue Jul 21, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fgxcs/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Aprogen, Inc. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - MacuCLEAR, Inc. - MingSight Pharmaceuticals - Molecular Design International, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - PanOptica, Inc. - Promedior, Inc. - R-Tech Ueno, Ltd. - Resolvyx Pharmaceuticals, Inc - RestorGenex Corporation - Sirnaomics, Inc. - Stelic Institute & Co. - Stemedica Cell Technologies, Inc. - Targazyme, Inc. - ThromboGenics NV - TWi Pharmaceuticals, Inc. Drug Profiles - 49-B - A-6 - A-717 - AC-301 - AKB-9778 - ALG-1001 - AP-202 - ATL-1103 - BDM-E - Beta-LGND2 - CLT-01001 - CLT-01007 - CLT-01012 - cyclosporine - Cyndacel-M - DG-3173 - DMX-200 - Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - DT-23552 - E-1086 - EG-Mirotin - emixustat hydrochloride - FP-008 - IB-09A0133 - IMD-0354 - JP-153 - L-779976 - LCB-030110 For more information visit http://www.researchandmarkets.com/research/7fgxcs/diabetic
GTXI: 0.55 (+0.01), OHRP: 2.62 (+0.10)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 15.37 (-0.32), GSK: 44.40 (+0.23), XNPT: 7.07 (+0.05), SYN: 1.72 (unch), OPXA: 4.18 (-0.01), FWP: 22.90 (+1.65), TEVA: 54.54 (+0.68), ABBV: 67.39 (+0.20), NVS: 82.34 (+0.26)
Acromegaly Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtgwjc/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegis Therapeutics, LLC - Antisense Therapeutics Limited - Chiasma, Inc. - Crinetics Pharmaceuticals, Inc. - DexTech Medical AB - Foresee Pharmaceuticals, LLC - GP Pharm, S.A. - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Novartis AG - Paladin Labs Inc. - Peptron, Inc. - Sompharmaceuticals S.A. Drug Profiles - ATL-1103 - BIM-23A758 - DG-3173 - FP-002 - G-02113 - ISIS-GHRLRx - ITF-2984 - L-779976 - octreotide - octreotide acetate - octreotide acetate LAR - octreotide acetate long acting - octreotide acetate SR - octreotide SR - pasireotide LAR - pegvisomant - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Somadex - SXN-101742 - SXN-101959 For more information visit http://www.researchandmarkets.com/research/mtgwjc/acromegaly
ISIS: 57.56 (-0.28), CHMA: 2.94 (+0.03), NVS: 82.34 (+0.26)
Antisense Therapeutics Limited - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:26AM CDT
Product Pipeline Review - 2014
Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h4bvf/proliferative) has announced the addition of the "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Proliferative Diabetic Retinopathy (PDR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Diabetic Retinopathy (PDR) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Antisense Therapeutics Limited - Icon Bioscience, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - Sirnaomics, Inc. - ThromboGenics NV Drug Profiles - ATL-1103 - BI-30089 - Lycium Anti-Angiogenic Proteoglycan - OC-10X - ocriplasmin (recombinant) - squalamine lactate - STP-601 For more information visit http://www.researchandmarkets.com/research/2h...liferative
OHRP: 2.62 (+0.10)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.91 (-0.02), LLY: 80.26 (+0.04), GSK: 44.40 (+0.23), BMY: 60.03 (-0.60), CTIC: 0.35 (unch), CNCE: 11.27 (+0.28), JNJ: 122.31 (-0.91), GILD: 79.65 (-0.01), AZN: 33.44 (-0.10), CCXI: 4.37 (+0.05), ICPT: 165.05 (+2.06), ABBV: 67.39 (+0.20)
Cortendo and Antisense Therapeutics signs exclusive licensing agreement for ATL1103 for acromegaly
M2 - Fri May 15, 5:56AM CDT
Cortendo AB (NOTC-A:CORT) (OTC:CRTOF), a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited (ASX:ANP), an Australian biopharmaceutical drug discovery and development company, announced on Thursday the entering into an exclusive license agreement that provides Cortendo with development and commercialisation rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
CORT: 5.81 (+0.04)
Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
BusinessWire - Fri May 15, 1:41AM CDT
--Cortendo Expands Investor Base Through New Private Placement
Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
BusinessWire - Thu May 14, 6:53PM CDT
Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics' ATL1103 for endocrinology applications.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 44.40 (+0.23), XNPT: 7.07 (+0.05), OPXA: 4.18 (-0.01), SYN: 1.72 (unch), ABBV: 67.39 (+0.20), TEVA: 54.54 (+0.68), NVS: 82.34 (+0.26)
Acromegaly - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqcstv/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acromegaly - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ipsen S.A. - Novartis AG - Antisense Therapeutics Limited - Paladin Labs Inc. - Camurus AB - GP Pharm, S.A. - Aegis Therapeutics, LLC - Peptron, Inc. - Q Chip Ltd. - Crinetics Pharmaceuticals, Inc. - Chiasma, Inc. - Foresee Pharmaceuticals, LLC - DexTech Medical AB For more information visit http://www.researchandmarkets.com/research/fqcstv/acromegaly
NVS: 82.34 (+0.26)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
ITEK: 6.94 (+0.05), REGN: 422.87 (+1.33)
